TTRX Stock Analysis: Buy, Sell, or Hold?
$13.45
0.76 (5.99%)
▲
5d:
+37.24%
30d:
+36.41%
90d:
+122.5%
WAIT
LOW Confidence
Analysis Updated: Sep 14, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When TTRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: TTRX is 13.6% above its trading range ($11.84). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: TTRX is 13.6% above its trading range ($11.84). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: TTRX is currently trading at $13.45, which is considered extended relative to its 30-day fair value range of $9.14 to $11.84.
Technical Outlook: Technically, TTRX is in a strong uptrend. Immediate support is located at $9.00, while resistance sits at $14.39. The stock is showing strong short-term momentum, up 6.0% recently.
Market Sentiment: TTRX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $26.00 (+93.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TTRX is in a strong uptrend. Immediate support is located at $9.00, while resistance sits at $14.39. The stock is showing strong short-term momentum, up 6.0% recently.
Market Sentiment: TTRX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $26.00 (+93.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$9.14 -
$11.84
Company Quality Score
32/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+13.6% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.0%)
- BULLISH: Trading 93.3% below Wall St target ($26.00)
- WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$9.14 -
$11.84
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$9.00
Resistance Level
$14.39
Current Trend
Strong Uptrend
Technical data as of
Sep 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-34.49
Wall Street Target
$26.00
(+93.3%)
Share & Embed Analysis
Last updated: September 15, 2026 12:55 AM ET
Data refreshes hourly during market hours. Next update: 1:55 AM
Data refreshes hourly during market hours. Next update: 1:55 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TTRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 48 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 51 HOLD |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 58 HOLD |